Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy

Published:2018-07 Issue: Volume:116 Page:111-113
ISSN:0306-9877
Container-title:Medical Hypotheses
language:en
Short-container-title:Medical Hypotheses

Author:

Qin Bao-Dong,Jiao Xiao-Dong,Zang Yuan-Sheng

Funder

Shanghai Sailing Program

Chinese National Natural Science

Young Start-up Foundation of Changzheng Hospital

Shanghai Municipal health and Family Planning Commission Foundation

Publisher

Elsevier BV

Subject

General Medicine

Reference14 articles.

1. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients;Ott;Clin Cancer Res,2013

2. Therapeutic antibodies against intracellular tumor antigens;Trenevska;Front Immunol,2017

3. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

4. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon;N Engl J Med,2015

5. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive analysis of single-cell RNA and bulk RNA sequencing based on M2 tumor-associated macrophage and angiogenesis-related genes to assess prognosis and therapeutic response in lung adenocarcinoma;Heliyon;2024-07

2. New clinical trial design in precision medicine: discovery, development and direction;Signal Transduction and Targeted Therapy;2024-03-04

3. Construction and validation of a novel signature based on epithelial-mesenchymal transition–related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment;Functional & Integrative Genomics;2022-12-20

4. Dynamic Expression of Palmitoylation Regulators across Human Organ Development and Cancers Based on Bioinformatics;Current Issues in Molecular Biology;2022-09-27

5. Consensus Molecular Subtypes Efficiently Classify Gastric Adenocarcinomas and Predict the Response to Anti-PD-1 Immunotherapy;Cancers;2022-07-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3